CIK 0001706431 · Large accelerated filer
Vir Biotechnology, Inc.
Sign in to watch- Ticker
- VIR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812730369
- Phone
- 415-906-4324
- Business address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,939
- in 1 filing, $42K under 10b5-1 plans
Net −$41,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-24 | SATO VICKI L Director | Sale 10b5-1 | −200 | $10.26 | $2K | 1,144,391 |
| 2026-02-24 | SATO VICKI L Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −42,377 | 0 | ||
| 2026-02-24 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 | −1,430 | $9.53 | $14K | 69,613 |
| 2026-02-24 | O'Byrne Jason EVP & Chief Financial Officer | Sale 10b5-1 | −1,634 | $9.53 | $16K | 162,615 |
| 2026-02-24 | Eisner Mark EVP and Chief Medical Officer | Sale 10b5-1 | −1,616 | $9.53 | $15K | 155,913 |
| 2026-02-24 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Sale 10b5-1 | −3,117 | $9.53 | $30K | 126,682 |
| 2026-02-24 | De Backer Marianne Chief Executive Officer | Sale 10b5-1 | −14,762 | $9.53 | $141K | 1,020,704 |
| 2026-02-23 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 | −1,829 | $7.45 | $14K | 71,043 |
| 2026-02-23 | O'Byrne Jason EVP & Chief Financial Officer | Sale 10b5-1 | −2,089 | $7.45 | $16K | 164,249 |
| 2026-02-23 | Eisner Mark EVP and Chief Medical Officer | Sale 10b5-1 | −2,089 | $7.45 | $16K | 157,529 |
| 2026-02-23 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Sale 10b5-1 | −4,445 | $7.45 | $33K | 129,799 |
| 2026-02-23 | De Backer Marianne Chief Executive Officer | Sale 10b5-1 | −19,039 | $7.45 | $142K | 1,035,466 |
| 2026-02-22 | Sabatini Brent SVP, Chief Accounting Officer | Grant or award 10b5-1 | +25,000 | 72,872 | ||
| 2026-02-22 | Sabatini Brent SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +50,000 | 50,000 | ||
| 2026-02-22 | O'Byrne Jason EVP & Chief Financial Officer | Grant or award 10b5-1 | +55,000 | 166,338 | ||
| 2026-02-22 | O'Byrne Jason EVP & Chief Financial Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +110,000 | 110,000 | ||
| 2026-02-22 | Eisner Mark EVP and Chief Medical Officer | Grant or award 10b5-1 | +55,000 | 159,618 | ||
| 2026-02-22 | Eisner Mark EVP and Chief Medical Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +110,000 | 110,000 | ||
| 2026-02-22 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Grant or award 10b5-1 | +55,000 | 134,244 | ||
| 2026-02-22 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Grant or award · Stock Option (Right to Buy) 10b5-1 | +110,000 | 110,000 |
Page 3 of 54 · 1,063 trades